Capricor Therapeutics, Inc. (CAPR) is a biopharmaceutical company engaged in the development of therapeutics for treating an array of diseases. The company’s pipeline product candidate includes CAP-1002 used for treating Duchenne muscular dystrophy and the cytokine storm in COVID-19 patients. The Company is also developing exosomes capable of delivering nucleic acids to treat different diseases.
The price of CAPR stock during the regular trading on January 24, 2022 was $2.83 with a decline of 2.08%. At last check in the premarket on January 25, 2022, the stock was significantly up by 7.42%.
CAPR: Events and Happenings
On January 25, 2022, CAPR reported about its entry into strategic collaboration with Japanese origin Nippon Shinyaku Company. The basic aim of the partnership is the commercialization and distribution of CAP-1002 in the US. On December 13, 2021, CAPR reported its vaccine and developmental portfolio updates mainly focusing on COVID-19. Company’s pre-clinical exosome mRNA vaccine has the capability for a strong T-cell response in a viral infection. In addition, the company will also report topline results from its INSPIRE Phase 2 studies in Q1 2022.
On November 12, 2021, CAPR reported that the company’s Executives presented at the Virtual TriLink Biotechnologies Annual mRNA Day Conference held on November 16, 2021.
CAPR: Key Financials
On November 09, 2021, CAPR announced its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.
Net Loss per Share
Basic and diluted net loss per share in Q3 2021 was $3.9 million, or $0.17 compared to $3.9 million, or $0.20 for the same period in 2020.
Assets
Total assets in Q3 2021 were recorded to be $43.1 million.
On September 24, 2021, CAPR reported optimistic final results for its HOPE-2 clinical studies utilizing CAP-1002. On September 22, 2021, CAPR reported that the company’s Executives presented at the conferences namely Virtual Cantor Fitzgerald Global healthcare Conference held on September 30 and Cell & Gene Meeting on the Mesa held on October 13, 2021.
Conclusion
CAPR stock is 40% down compared to the last six months period due to the challenges faced by the economy because of the worsening pandemic situation. The current premarket increase in stock price is the consequence of the company’s announcement of its entry into a strategic partnership. The analysts are confident that the current market scenario is favorable for the company’s stock to bloom.
